AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31750800 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 50
Study 30084882 — intervention group
Group type: EXPERIMENTAL
Intervention: Protease inhibitor monotherapy (PIM)
Number of subjects: 76
Study 30084882 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy
Number of subjects: 76
Study 27988044 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% tea seed oil remover
Number of subjects: 20
Study 27988044 — intervention group
Group type: EXPERIMENTAL
Intervention: Tea seed oil remover
Number of subjects: 20
Study 27988044 — intervention group
Group type: COMPARATOR
Intervention: Benchmark (olive oil)
Number of subjects: 20
Study 25791806 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal nanoparticle encapsulating prednisolone (LN-PLP) 1.5mg/kg
Number of subjects: 30
Study 25791806 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal nanoparticle encapsulating prednisolone (LN-PLP)
Number of subjects: 30
Study 25791806 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 24113599 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine culture screening intervention for ESBL-EK; patients colonized or infected were placed in a private room with contact precautions.
Number of subjects: 0
Study 24113599 — intervention group
Group type: COMPARATOR
Intervention: Control hospital (no specific intervention mentioned).
Number of subjects: 0
Study 20410908 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal warming mattresses
Number of subjects: 39
Study 20410908 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene wrap
Number of subjects: 39
Study 18791483 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal combination therapy (Hypericum perforatum and Vitex agnus-castus)
Number of subjects: 100
Study 18791483 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 100
Study 17761978 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide (400 mg daily)
Number of subjects: 119
Study 17761978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 15051843 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal supplementation
Number of subjects: 429
Study 15051843 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnatal intake of supplementation (0.10 to 0.20 MJ/d)
Number of subjects: 429
Study 15051843 — intervention group
Group type: COMPARATOR
Intervention: Postnatal intake of supplementation (excess of 0.20 MJ/d)
Number of subjects: 429
Study 15051843 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnatal supplementation among women born thin
Number of subjects: 429
Study 11174744 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-stat
Number of subjects: 168
Study 11174744 — intervention group
Group type: COMPARATOR
Intervention: pH-stat
Number of subjects: 168
Study 11174744 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-stat and pH-stat
Number of subjects: 168
Study 11090583 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-down tilt during Exercise treatment (15 min cycling at 70% maximal O2 uptake)
Number of subjects: 6
Study 11090583 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-up tilt during Exercise treatment
Number of subjects: 6
Study 11090583 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-up tilt during No-Exercise treatment (30 min resting)
Number of subjects: 6
Study 11090583 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-down tilt during No-Exercise treatment
Number of subjects: 6
Study 11090583 — intervention group
Group type: COMPARATOR
Intervention: Head-down tilt compared to head-up tilt
Number of subjects: 6
Study 12206029 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Optimized Stannous Fluoride (COSF) dentifrice (0.454% stannous fluoride)
Number of subjects: 0
Study 12206029 — intervention group
Group type: COMPARATOR
Intervention: Control dentifrice
Number of subjects: 0
Study 8476620 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental 5 mg/kg (Group 1)
Number of subjects: 48
Study 8476620 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 1.5 mg/kg (Group 2)
Number of subjects: 48
Study 8476620 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental 3 mg/kg plus fentanyl 4 to 6 micrograms/kg (Group 3)
Number of subjects: 48
Study 8476620 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg/kg plus fentanyl 4 to 6 micrograms/kg (Group 4)
Number of subjects: 48
Study 3510638 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin (2 g every four hours for four doses)
Number of subjects: 118
Study 3510638 — intervention group
Group type: COMPARATOR
Intervention: Moxalactam (2 g every four hours for four doses)
Number of subjects: 118
Study 29792554 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (250 mg three times a day)
Number of subjects: 19
Study 29792554 — intervention group
Group type: EXPERIMENTAL
Intervention: Methazolamide (100 mg twice a day)
Number of subjects: 19
Study 29792554 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 27389034 — intervention group
Group type: EXPERIMENTAL
Intervention: CAFAP intervention (8 weeks duration)
Number of subjects: 56
Study 27389034 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 56
Study 24013268 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised dual-task home-based programme performed six days a week for seven weeks.
Number of subjects: 16
Study 22710649 — intervention group
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil/chlorthalidone 40/25 mg
Number of subjects: 1071
Study 22710649 — intervention group
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil/chlorthalidone 80/25 mg
Number of subjects: 1071
Study 22710649 — intervention group
Group type: COMPARATOR
Intervention: Olmesartan/hydrochlorothiazide 40/25 mg
Number of subjects: 1071
Study 19748210 — intervention group
Group type: EXPERIMENTAL
Intervention: Retroperitoneal approach (Group I)
Number of subjects: 34
Study 19748210 — intervention group
Group type: COMPARATOR
Intervention: Transperitoneal approach (Group II)
Number of subjects: 34
Study 19748210 — intervention group
Group type: COMPARATOR
Intervention: Transperitoneal approach (Group III)
Number of subjects: 34
Study 18617877 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral trioxide aggregate
Number of subjects: 50
Study 18617877 — intervention group
Group type: EXPERIMENTAL
Intervention: White Portland cement
Number of subjects: 50
Study 18617877 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitremer
Number of subjects: 50
Study 18617877 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji Ortho
Number of subjects: 50
Study 18617877 — intervention group
Group type: COMPARATOR
Intervention: Silver amalgam
Number of subjects: 50
Study 16544870 — intervention group
Group type: EXPERIMENTAL
Intervention: Home health exercise and problem solving intervention (Reducing Disability in Alzheimer's Disease, or RDAD)
Number of subjects: 0
Study 16544870 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 12428818 — intervention group
Group type: EXPERIMENTAL
Intervention: Alexander Technique
Number of subjects: 93
Study 12428818 — intervention group
Group type: COMPARATOR
Intervention: Massage
Number of subjects: 93
Study 12428818 — intervention group
Group type: COMPARATOR
Intervention: No additional intervention
Number of subjects: 93
Study 10600919 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal fat with preload of banana shake
Number of subjects: 24
Study 10600919 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxiglumide (CCK‐A receptor antagonist) with intraduodenal fat and preload of banana shake
Number of subjects: 24
Study 10600919 — intervention group
Group type: COMPARATOR
Intervention: Saline with preload of banana shake
Number of subjects: 24
Study 10600919 — intervention group
Group type: COMPARATOR
Intervention: Saline perfusion with preload of banana shake
Number of subjects: 24
Study 8949807 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% hyperbaric bupivacaine at L3-4 interspace (n=15)
Number of subjects: 30
Study 8949807 — intervention group
Group type: COMPARATOR
Intervention: 0.5% hyperbaric bupivacaine at L4-5 interspace (n=15)
Number of subjects: 30
Study 1771945 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose (3 x 100 mg/day)
Number of subjects: 24
Study 1771945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 30256796 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 1431
Study 27566855 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg monthly
Number of subjects: 1097
Study 27566855 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg PRN
Number of subjects: 1097
Study 27566855 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 2.0 mg monthly
Number of subjects: 1097
Study 27566855 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 2.0 mg PRN
Number of subjects: 1097
Study 27566855 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 2.0 mg monthly (extra-large group, PEDs ≥352 μm)
Number of subjects: 1097
Study 25061716 — intervention group
Group type: COMPARATOR
Intervention: Control Formula (CF)
Number of subjects: 180
Study 25061716 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula supplemented with 8 g GOS/L (EF8)
Number of subjects: 180
Study 25061716 — intervention group
Group type: EXPERIMENTAL
Intervention: Human Milk (HM)
Number of subjects: 180
Study 25061716 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula supplemented with 4 g GOS/L (EF4)
Number of subjects: 180
Study 22143621 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy-dense (LE) foods (30 kcal per 100 g)
Number of subjects: 27
Study 22143621 — intervention group
Group type: COMPARATOR
Intervention: High-energy-dense (HE) foods (130 kcal per 100 g)
Number of subjects: 27
Study 22143621 — intervention group
Group type: EXPERIMENTAL
Intervention: Food texture (liquid or semi-solid)
Number of subjects: 27
Study 20381802 — intervention group
Group type: EXPERIMENTAL
Intervention: Covered SEMS
Number of subjects: 80
Study 20381802 — intervention group
Group type: COMPARATOR
Intervention: Uncovered SEMS
Number of subjects: 80
Study 18410231 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately high salt intake (11.2 g/d) with high calcium diet (1284 mg)
Number of subjects: 11
Study 18410231 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately low calcium intake (518 mg)
Number of subjects: 11
Study 18410231 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately high salt intake (11.2 g/d) with low calcium diet (518 mg)
Number of subjects: 11
Study 18410231 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately low salt intake (3.9 g/d) with low calcium diet (518 mg)
Number of subjects: 11
Study 18410231 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately low salt intake (3.9 g/d) with high calcium diet (1284 mg)
Number of subjects: 11
Study 17221036 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.8 microg/kg)
Number of subjects: 62
Study 17221036 — intervention group
Group type: COMPARATOR
Intervention: Control (0.9% saline solution)
Number of subjects: 62
Study 12811320 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavored Colyte
Number of subjects: 130
Study 12811320 — intervention group
Group type: COMPARATOR
Intervention: Unflavored Colyte
Number of subjects: 130
Study 11286044 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (0.75 mg daily)
Number of subjects: 22
Study 11286044 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 22
Study 11286044 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 11286044 — intervention group
Group type: EXPERIMENTAL
Intervention: Primidone
Number of subjects: 22
Study 8978953 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with systemic sclerosis (SSc)
Number of subjects: 32
Study 8978953 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 32
Study 1449200 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard regimen of four (40 ml) or eight (80 ml) ampules of antivenom
Number of subjects: 118
Study 1449200 — intervention group
Group type: EXPERIMENTAL
Intervention: Three Brazilian polyspecific antivenoms
Number of subjects: 118
Study 6731758 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrostimulation anesthesia combined with nitrous oxide (ESA)
Number of subjects: 22
Study 6731758 — intervention group
Group type: COMPARATOR
Intervention: Inhalation anesthesia with enflurane-nitrous oxide (EFL)
Number of subjects: 22
Study 6731758 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (ESA and EFL)
Number of subjects: 22
Study 30606240 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-linear periodized resistance training
Number of subjects: 0
Study 30606240 — intervention group
Group type: COMPARATOR
Intervention: Traditional non-periodized resistance training
Number of subjects: 0
Study 30503595 — intervention group
Group type: EXPERIMENTAL
Intervention: CoreValve (CV)
Number of subjects: 675
Study 30503595 — intervention group
Group type: COMPARATOR
Intervention: SAPIEN XT (SXT)
Number of subjects: 675
Study 30503595 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolut R (ER)
Number of subjects: 675
Study 30503595 — intervention group
Group type: COMPARATOR
Intervention: SAPIEN 3 (S3)
Number of subjects: 675
Study 25193570 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative procedures
Number of subjects: 36
Study 25193570 — intervention group
Group type: COMPARATOR
Intervention: Conservative procedures
Number of subjects: 36
Study 25341445 — intervention group
Group type: EXPERIMENTAL
Intervention: Podcast
Number of subjects: 36
Study 25341445 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain language summary
Number of subjects: 36
Study 25341445 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcript
Number of subjects: 36
Study 25341445 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstract
Number of subjects: 36
Study 21543992 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective laser trabeculoplasty (SLT)
Number of subjects: 69
Study 21543992 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy (prostaglandin analog)
Number of subjects: 69
Study 21180796 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral compaction (LC)
Number of subjects: 52
Study 21180796 — intervention group
Group type: EXPERIMENTAL
Intervention: Tagger's hybrid (TH)
Number of subjects: 52
Study 21180796 — intervention group
Group type: EXPERIMENTAL
Intervention: MicroSeal (MS)
Number of subjects: 52
Study 21180796 — intervention group
Group type: EXPERIMENTAL
Intervention: GuttaFlow (GF)
Number of subjects: 52
Study 17878467 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchodilators (beta(2)-agonists and anticholinergics), including once-a-day preparations and combination products with inhaled steroids.
Number of subjects: 0
Study 17878467 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-inflammatory agents under development for COPD.
Number of subjects: 0
Study 17878467 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation treatments.
Number of subjects: 0
Study 16271677 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonographic-guided approach
Number of subjects: 60
Study 16271677 — intervention group
Group type: COMPARATOR
Intervention: Traditional landmark approach
Number of subjects: 60
Study 11907489 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical administration of 0.1% 8-methoxypsoralen cream
Number of subjects: 8
Study 11907489 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical administration of 3 mg/L 8-methoxypsoralen bath
Number of subjects: 8
Study 11907489 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of 0.6 or 1 mg/kg 8-methoxypsoralen
Number of subjects: 8
Study 9485534 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 0
Study 9485534 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7842186 — intervention group
Group type: EXPERIMENTAL
Intervention: Uniphyl (theophylline), once daily
Number of subjects: 32
Study 7842186 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol (200 micrograms four times per day)
Number of subjects: 32
Study 7842186 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Uniphyl and salbutamol
Number of subjects: 32
Study 7842186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 2218718 — intervention group
Group type: EXPERIMENTAL
Intervention: Active group (pulsed electromagnetic fields)
Number of subjects: 195
Study 2218718 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 195
Study 365289 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard drug treatment plus intermittent positive-pressure ventilation (IPPV)
Number of subjects: 0
Study 365289 — intervention group
Group type: COMPARATOR
Intervention: Standard drug treatment alone
Number of subjects: 0
Study 31050982 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal Magnetic Innervation (ExMI) therapy
Number of subjects: 52
Study 31050982 — intervention group
Group type: COMPARATOR
Intervention: No therapeutic intervention (Control group)
Number of subjects: 52
Study 29349982 — intervention group
Group type: COMPARATOR
Intervention: 20 ml physiological saline (Group A)
Number of subjects: 160
Study 29349982 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml tranexamic acid and 10 ml physiological saline (Group B)
Number of subjects: 160
Study 29349982 — intervention group
Group type: COMPARATOR
Intervention: 20 ml physiological saline (Group C)
Number of subjects: 160
Study 29349982 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml tranexamic acid and 10 ml physiological saline (Group D)
Number of subjects: 160
Study 29349982 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 160
Study 26849923 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cyclophosphamide (Group A)
Number of subjects: 60
Study 26849923 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral mycophenolate mofetil (MMF) (Group B)
Number of subjects: 60
Study 23681364 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD9773 cohort 1 (250/50 U/kg)
Number of subjects: 20
Study 23681364 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD9773 cohort 2 (500/100 U/kg)
Number of subjects: 20
Study 23681364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 21281874 — intervention group
Group type: EXPERIMENTAL
Intervention: Novo-Helisen Depot, A alternata 100%
Number of subjects: 50
Study 21281874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 19566116 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cyclosporin
Number of subjects: 536
Study 19566116 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin withdrawal
Number of subjects: 536
Study 19566116 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose cyclosporin
Number of subjects: 536
Study 16565000 — intervention group
Group type: EXPERIMENTAL
Intervention: Foldable iris-claw phakic intraocular lens (pIOL) implantation
Number of subjects: 41
Study 12647600 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg/d; n = 5,170)
Number of subjects: 10355
Study 12647600 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 5,185)
Number of subjects: 10355
Study 12647600 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 10355
Study 12647600 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 10355
Study 10579150 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 800 mg with bupropion SR 300 mg (two 150 mg tablets)
Number of subjects: 24
Study 10579150 — intervention group
Group type: COMPARATOR
Intervention: Bupropion SR 300 mg alone (two 150 mg tablets)
Number of subjects: 24
Study 8916632 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotionally focused therapy (EFT)
Number of subjects: 32
Study 8916632 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 32
Study 1886157 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen therapy (2 or 5 years)
Number of subjects: 1846
Study 1886157 — intervention group
Group type: COMPARATOR
Intervention: Control (no adjuvant endocrine therapy)
Number of subjects: 1846
Study 6229567 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% reduction in lithium dosage
Number of subjects: 72
Study 6229567 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% reduction in lithium dosage
Number of subjects: 72
Study 6229567 — intervention group
Group type: COMPARATOR
Intervention: Usual dose of lithium (control)
Number of subjects: 72
Study 30394541 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolstered standard of care (BSOC) services plus an economic-strengthening intervention
Number of subjects: 0
Study 30394541 — intervention group
Group type: COMPARATOR
Intervention: Bolstered standard of care (BSOC) services
Number of subjects: 0
Study 28182510 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume plyometric training (LPT)
Number of subjects: 25
Study 28182510 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume plyometric training (HPT)
Number of subjects: 25
Study 27084661 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton Beam Radiation Therapy
Number of subjects: 69
Study 27084661 — intervention group
Group type: COMPARATOR
Intervention: Transarterial Chemoembolization (TACE)
Number of subjects: 69
Study 25438482 — intervention group
Group type: EXPERIMENTAL
Intervention: NitroSense Derma Protect patch (24 mg, releasing 9 nmol/cm2/min of nitric oxide for 3 hours every other day for 3 weeks)
Number of subjects: 50
Study 25438482 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 50
Study 25438482 — intervention group
Group type: EXPERIMENTAL
Intervention: NitroSense Derma Protect patch
Number of subjects: 50
Study 22438367 — intervention group
Group type: EXPERIMENTAL
Intervention: IMNCI programme implementation
Number of subjects: 59680
Study 22438367 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 59680
Study 19497197 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir 1.0 mg/d
Number of subjects: 32
Study 19497197 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32